Copy number variants associated with 18p11.32, DCC and the promoter 1B region of APC in colorectal polyposis patients

Amy L. Masson a,b, Bente A. Talseth-Palmer a,b, Tiffany-Jane Evans a,b, Patrick McElduff c,d, Allan D. Spigelman e,f,g, Garry N. Hannan h, Rodney J. Scott a,b,⁎

a Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, 2305, Australia
b Centre for Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales, 2308, Australia
c School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, New South Wales, 2305, Australia
d Centre for Information-Based Medicine, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, 2305, Australia
e Hereditary Cancer Clinic, St Vincent’s Hospital, The Kinghorn Cancer Centre, Sydney, New South Wales, 2010, Australia
f Centre for Public Health, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, 2305, Australia
g Healthy Ageing, Elderly Health Research Group, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, New South Wales, 2308, Australia
h Hunter Family Cancer Service, Hunter New England Area Health, Newcastle, New South Wales, 2305, Australia
i Division of Molecular Medicine, Hunter Area Pathology Service, John Hunter Hospital, Newcastle, New South Wales, 2305, Australia

A B S T R A C T

Familial Adenomatous Polyposis (FAP) is the second most common inherited predisposition to colorectal cancer (CRC) associated with the development of hundreds to thousands of adenomas in the colon and rectum. Mutations in APC are found in ~80% polyposis patients with FAP. In the remaining 20% no genetic diagnosis can be provided suggesting other genes or mechanisms that render APC inactive may be responsible. Copy number variants (CNVs) remain to be investigated in FAP and may account for disease in a proportion of polyposis patients. A cohort of 56 polyposis patients and 40 controls were screened for CNVs using the 2.7M microarray (Affymetrix) with data analysed using ChAS (Affymetrix). A total of 142 CNVs were identified in the patients screened that was of particular interest. Further investigation is necessary to fully understand the role of these variants in CRC risk given the high prevalence among the patients screened.

1. Introduction

FAP is an autosomal dominant inherited disease, which affects nearly 1 in 12,000 individuals and accounts for approximately 0.5% of all CRCs. Typically, FAP is characterized by the early development of hundreds to thousands of adenomas in the colon and rectum. The development of adenomas commences during early childhood and adolescence and commonly becomes malignant if untreated, with an average age of cancer onset of 35–36 years. A less severe form of FAP termed attenuated FAP is characterized by fewer adenomas and a later age of disease onset (Lynch and de la Chapelle, 2003; Rustgi, 2007).

Mutations in the APC gene were found to be the genetic basis of FAP and since its discovery over 1500 pathogenic mutations have been reported (Fokkema et al., 2011; Stenson et al., 2009). Up to 20% of polyposis patients do not have a family history of disease but do harbour germline APC mutations. Mutations in the APC gene account for the majority of patients diagnosed with FAP and more recently, mutations in the base excision repair gene MUTHY have been shown to be associated with a recessive form of colorectal polyposis (Pezzi et al., 2009). Up to 20% polyposis patients that are clinically tested for mutations in these genes do not have a germline mutation and no genetic diagnosis for their disease.

Abbreviations: ALL, acute lymphoblastic leukaemia; BH, Bengamini and Hochberg; CHAS, Chromosome Analysis Suite; CN, copy number; CNV, copy number variation; COSMIC, Catalogue of Somatic Mutations in Cancer; CRC, colorectal cancer; DGV, Database of genomic variants; DNA, deoxyribonucleic acid; FAP, familial adenomatous polyposis; HMDD, human microRNA disease database; Kb, Kilobase; KEGG, Kyoto Encyclopaedia of Genes and Genomes; lncRNA, long non-coding RNA; MMR, mismatch repair; MLPA, multiplex ligation-dependent probe amplification; NTC, no template control; QC, quality control; RNA, ribonucleic acid; SNP, single nucleotide polymorphism; UCSC, University of California, Santa Cruz.  
⁎ Corresponding author at: Information Based Medicine Program, Hunter Medical Research Institute, Level 3 West, New Lambton Heights, New South Wales, 2305, Australia.  
E-mail address: Rodney.Scott@newcastle.edu.au (R.J. Scott).
CNVs represent a form of structural genetic variation associated with a gain or loss of genomic material. CNVs have been shown to contribute to the development of disease directly through the disruption of functional gene sequences; via promoter region inactivation; or as a result of more cryptic changes such as alterations in epigenetic marks, changes to microRNA controlling species, transcription read through, unmasking recessive alleles and via disruption of non-coding gene sequences (Stella et al., 2007; Morak et al., 2011; Clendenning et al., 2011; Chan et al., 2001; Litzenberg et al., 2009; Hochstenbach et al., 2012).

Furthermore, while CNVs which are commonly observed in the population may contain cancer related genes, it is the rare CNVs (low population frequencies) which are proposed to harbour genes or other regulatory elements that are likely to be disease susceptibility factors (Shlien and Malkin, 2010). Several studies have recently investigated the contribution of rare CNVs in cancer; one study identified 26 rare CNVs which they proposed to contribute to breast cancer susceptibility, while another has reported the enrichment of disrupted genes that affect the maintenance of genomic integrity i.e. DNA double-strand break repair also in familial breast cancer (Krepischi et al., 2012; Pylkas et al., 2012).

In this study we have focused on the role of CNVs in the genomes of patients diagnosed with polyposis that do not harbour germline mutations in APC or MUTYH as assessed by direct DNA sequencing and multiplex ligation probe amplification (MLPA). High throughput microarray technology has continuously improved since its introduction such that now continually smaller CNVs can be detected in ever larger patient cohorts. We used the Affymetrix Cyto2.7M microarray, which at the time of this study provided the highest genomic coverage of any commercially available microarray; containing 400,000 SNP probes and >2.1 million CNV probes with an average spacing of 1395 base pairs (bp). CNV analysis was conducted on DNA derived from 56 polyposis patients (APC/MUTYH mutation negative) and compared to 40 controls and the Database of Genomic Variants (DGV) with the aim of identifying CNVs, which may be involved in the pathogenesis of the observed disease.

2. Methods

2.1. Samples

The study including patient recruitment and all experimental protocols were approved by the Hunter New England Human Research Ethics Committee and the University of Newcastle Human Research Ethics Committee. The methods employed in this study were carried out in accordance with the approved guidelines of the University of Newcastle. Genomic DNAs were obtained from polyposis patients who had given informed consent for their DNA to be used for studies into their disease and control DNA samples from the Hunter Community Study was used in the current study (McEvoy et al., 2010). DNA was extracted from whole blood by the salt precipitation method (Miller et al., 1988).

The inclusion criteria for this study was a patient diagnosed with adenomatous polyposis or and who did not have a detectable APC or MUTYH mutation as assessed by complete Sanger sequencing and MLPA analysis. A cohort of 56 clinically histologically confirmed polyposis patients was used in this study. All patients were unrelated and were diagnosed after colorectal resection who then sought genetic testing for their condition. The average age of diagnosis was 51 years (range 10–74), 32 of the probands had a family history of colonic polyposis or CRC, 21 had no family history and for 3 patients no information on family history was available (see Table 1 in Masson et al., submitted for publication). Polyp counts ranged from 5 through to over 1000, however most patients had less than 100 polyps suggesting that the majority of patients presented with an attenuated form of polyposis. From the 55 patients examined for CNVs in this study 8 were diagnosed with typical polyposis and the remaining 47 were diagnosed with attenuated form of the disease (see Table 1 in Masson et al., submitted for publication).

The control patients were all over 55 years of age and healthy at the time of phlebotomy. None had reported any change in bowel habits prior to blood collection. A total of 96 samples were included in the study.

2.2. Genomic array preparation and data processing

The genomic DNA was processed on the Affymetrix Cyto2.7M array according to manufacturer’s protocols. Affymetrix Chromosome Analysis Suite (ChAS) (Version CytoB-N1.2.0.232; r4280) was used to analyse the array data (NetAffx Build 30.2 (Hg18) annotation).

A training set of 20 randomly selected samples was used to further optimize a series of quality control (QC) parameters reduce the number of false-positive CNVs being included in the analysis as many of these QC thresholds were more stringent than default settings alone.

The Cyto2.7M array is comprised of both CNV probes and SNP probes. For the confident detection of CNVs samples were required to have a minimum quality threshold of: mapQC <0.27 (Median Absolute Pair-wise Difference; QC of CN probes compared to a reference model); snpQC >1.1 (SNP probe QC measuring distances between the distribution of alleles AA, AB and BB alleles in which larger differences in allele distribution is associated with an increased ability to call a given genotype); and wavinessSd <0.1 (measure of standard deviation in data waviness; the GC content across the genome correlates with average probe intensities).

For the data that fulfilled the array performance QC, CNV calling QC was then undertaken to minimise the inclusion of false positive or negative CNV calls being incorporated into the analysis. This included evaluation of CNV calls with respect to having >90% confidence, a CNV having to be of autosomal origin (not located on either sex chromosome), and CNVs had to have a minimum of 24 probes used to call the CNV region. Visual inspection was used to confirm all CNV calls, verify the suggested CN state, and to further identify regions associated with low marker coverage and excluded across all samples (i.e. centromeric and telomeric regions; see Table 2 in Masson et al., submitted for publication). The smallest CNV detected with confidence was 6.03 Kilobases (Kb) across all samples.

2.3. CNV and statistical analysis

CNVs were subject to a series of analyses which included: (Galiatsatos and Foulkes, 2006) Identification of abundant genomic regions and genes affected by a CNV in patients; (Lynch and de la Chapelle, 2003) Statistical assessment of the distribution of CNVs across the genome of patients compared to controls; and (Rustgi, 2007) interrogation of CNV data for CN gains and losses residing in or ±100 Kb of 77 genes comprising the WNT signalling and mismatch repair (MMR) pathways as well as other reported CRC susceptibility genes, likely to be associated with polyposis (see Table 3 in Masson et al., submitted for publication) (Pezzi et al., 2009; Molatore et al., 2010). Associations (e.g. numbers and sizes of CNVs) were statistically compared between patients and controls using a two tailed un-paired t-test Graphpad Prism (Version 6; available http://www.graphpad.com/quickcalcss/ttest1/). The derived p-values were corrected for multiple testing using Bonferroni correction (Alpha = 0.05, R = 22). The Bonferroni’s adjustment resulted in the confidence level being <0.0023.

2.4. Validation of CNV results

CN gains and losses were subject to validation using pre-designed TaqMan Copy Number Assays (Applied Biosystems). Where possible, two CN assays (test assays) located within and two located just outside (control assay) the CNV of interest were utilized (assay information
summarized in Table 4 in Masson et al., submitted for publication). The sample(s) of interest were tested along with a no template control (NTC) and several calibrator samples (of known CN for the region assessed). All samples were assayed in triplicate and real-time PCR was conducted according to manufacturer's instructions using 10 ng of DNA sample in a final reaction volume of 20 μL. Using the real-time PCR (Applied Biosystems 7500; SDS software Version v1.4) the assay was run according manufacturer's protocols. CopyCaller v2.0 software (Applied Biosystems) was used to analyse the results.

Several CNVs were further validated using this independent method (see Table 5 in Masson et al., submitted for publication). These CNVs included both CN gains and CN losses in the genes DCC and APC as well as in the genomic region 18p11.32. As we observed high concordance between array data and all CNVs were validated using an independent method, it was considered unnecessary to confirm every CNV identified as analysis parameters were consistent across all samples.

For the variant identified in the promoter region of the APC gene family studies were undertaken and the result was confirmed in a number of affected relatives. Unfortunately, we were unable to extend this aspect of the study for other potentially causative CNVs due to either there being no living affected relative or any other person diagnosed with disease in the respective family.

2.5. Pathway analysis and annotation

In silico analysis conducted in this study involved the analysis of 49 of the 148 genes unique to the patients that were also considered rare as they have not been reported in the DGV.

Pathway analysis was performed using WebGestalt software (Version 2013) (Zhang et al., 2005). This software was used to assess gene lists derived from the refined CNV results obtained from ChAS according to Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways, cytoband enrichment analysis, and miR targets. Analysis was performed using hypergeometric statistical method, Benjamini and Hochberg (BH) correction for multiple testing and a biological significance threshold of <0.05 with a minimum of two genes per category required to assess any enrichment.

TAM (Tool for Annotations of miRs) (Version 2) (Lu et al., 2010) software was used to annotate miRs according to miR family, cluster, function, Human miR associated disease database (HMDD) and tissue specificity. Annotations were performed using the following parameters: all miRs in the TAM database were used as a background; to identify meaningful categories we looked at miR over-representation in all categories and analysis was limited to at least one miR in a given category. Enrichment analysis for miRs categories was conducted using hypergeometric testing and p-values were corrected according to Bonferroni correction for multiple testing.

3. Results

3.1. Array resolution and CNV detection

A total of 278 CNVs were identified in the 96 participants involved in this study (Table 1). CNVs ranged in size from 6.03 Kb to 1435.95 Kb. The average number of CNVs identified per sample did not differ significantly between patients and controls (p = 0.4383) nor did the average CNV burden (p = 0.5173) or average CNV size (p = 0.1664).

3.2. Abundant genomic regions and genes associated with CNVs

Analysis of the control population revealed a total of 104 CNVs of which 12 genomic regions were disrupted by a CNV in more than one individual. Eight of the genomic regions (2p16.1, 4p15.31, 4q13.1, 5p13.3, 5q21.2, 7p14.1, 8q12.1 and 8q24.23) were disrupted by a CNV in two unrelated individuals; three genomic regions (4q32.2, 6q22.31 and 12p13.31) were disrupted by a CNV in three control participants; and one genomic region (3q26.31) was found to be affected in five individuals (see Table 6 in Masson et al., submitted for publication). In total 66 of the 104 CNVs (63.46%) disrupted 96 genes. The 96 genes disrupted by CNVs were screened against the current cancer genome census list (COSMIC database available: http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) to determine whether any were likely to be associated with cancer. None of these genes were in common with those known to be associated with a cancer predisposition. Three CNVs were identified to disrupt MLL3, PBB1 and PLAG1, respectively, that have been observed in medulloblastomas, pre-BALL/myoepitheliomas and salivary adenomas.

Of the 174 CNVs identified in the polyposis patients, 15 genomic regions disrupted by a CNV (comprising 32 CNVs detected in 28 unrelated patients) were common to regions also disrupted by a CNV in the controls (see Table 7 in Masson et al., submitted for publication). These CNVs were not included in further analysis as they were considered most likely to be neutral. Of the remaining 142 CNVs unique to the patients, 6 genomic regions contained CNVs which were common to multiple patients (Table 2). The genomic region 2q32.3, was disrupted by a CNV in two patients, as were the CNVs that encompassed regions located at 2q34, 3q26.1 and 4q12; one genomic region (3q26.32) was disrupted by a CNV in three patients; and another genomic region (18p11.32) was disrupted by a CNV in five patients.

In three patients CNVs located 6p12.3, 20p12.1 and 22q12, respectively, harboured large deletions encompassing part of the genes SERT1, MACROD2 and SYN3 and were subject to special consideration as the three genes were also affected by CNV changes in 3 control subjects (see Fig. 1). Two of the deletions occurring in the patients encompassed coding regions of SERT1 (exons 4-10) and SYN3 (exons 7-9) suggesting a loss of gene function in both instances. The SERT1 CNV in another control subject occurred in intron 2 and appears to be less likely to affect function. The SYN3 CNV in a control subject was a duplication that included exons 4 and 5 and which did not alter the reading frame of SYN3 and may have affected gene function. The CNV affecting MACROD2 in intron 5 of a polyposis patient appeared not to alter exonic structure of the gene. Similarly, a control subject was also found to harbour a CNV in intron 5 of MACROD2 but residing 5' to that identified in the patient. Neither CNV encompassed an exon. Since two adjacent deletions in intron 5 of MACROD2 were observed that did not appear to alter the exonic structure of the gene they were not considered to be disruptive.

### Table 1

| CNV Count | CNV Size (Kb) |
|-----------|---------------|
| Total CNV affected genome per group | Mean total CNV affected genome per sample |
| Median CNVs per sample | Mean CNVs per sample |
| 56 | 2 |
| 40 | 2 |
| 2 |
| 3.11 |
| 2.6 |
| 0.4383 |
| 14,018.83 |
| 11,820.75 |
| 0.5173 |
| 250.34 |
| 295.52 |
| 106.57 |
| 82.18 |
| 104 |

*statistically significant
Exon 1 and extending into the irritable bowel disease (IBD) locus (Hetzenecker et al., 2012) is intriguing and suggests there may be a relationship between IBD and colorectal malignancy. The distribution of CNVs across chromosomes was compared between patients and controls revealing no statistically significant differences in CNV distribution. We did observe a trend in the overrepresentation of CNVs in patients (CNVs = 9) compared to controls (CNVs = 0) using Fisher’s exact test for chromosome 18 \((p = 0.009)\) which did not remain statistically significant after correction for multiple testing (i.e. \(p = 0.0022\)). Among the CNVs located on chromosome 18, a CNV gain was detected in the first intron of the DCC gene \((18:48,381,778-48,412,417; 30.6\ Kb; 93\%\) confidence, detected by 52 probes\), which was subsequently confirmed by TaqMan CN assays (see Fig. 2).

A CNV gain was also identified in one patient which encompassed exon 1 and extending into the first intron of the USP14 gene located on chromosome 18 \((18:50,739-154,914, size 104\ Kb; 90\%\) confidence and detected by 34 probes\). This CNV encompassing part of the irritable bowel disease (IBD) locus (Hetzenecker et al., 2012) is intriguing and suggests there may be a relationship between IBD and colorectal malignancy.

### 3.3. Distribution of CNVs across the genome in patients

Of note, five patients harboured the same CNV loss at the 18p11.32 locus (Fig. 3). The predicted size of the largest CNV identified a loss of 82.48 Kb \((93\%\) confidence and detected by 65 probes\); three other unrelated patients all harboured a similar sized CNV loss of 79.92 Kb \((all \sim 91\%\) confidence and detected by 63 probes\); and one patient was found to have a CNV loss of 51.84 Kb \((94\%\) confidence and detected by 59 probes\). All CNVs located in the 18p11.32 region overlapped each other by 10.14 Kb and this was confirmed by TaqMan CN assay to be lost in all five patients. This region of loss is proposed to contain the long non-coding RNA \((Inc-RNA)\) TCONS_00026231 \((18:1,963,908-1,972,876\) Hg19; UCSC Genome Browser).

### 3.4. CRC susceptibility gene interrogation

We determined whether CNVs within 100 Kb either side of 77 genes involved in pathways known to be associated with CRC risk, including members of the WNT signalling and MMR pathways (see Table 3 in Masson et al., submitted for publication), could potentially contribute to CRC development. Two unrelated polyposis patients harboured a CNV in the vicinity of the MLH1 and CTNNB1 genes, respectively. One patient harboured a CNV loss 18 Kb upstream MLH1 located 3:36,925,248-36,991,856 \((66.6\ Kb, 95\%\) confidence and detected by 35 probes\) while the other harboured a CNV loss extending upstream and into the promoter region of CTNNB1 located 3:41,068,578-41,119,502 \((50.9\ Kb, 94\%\) confidence and detected by 24 probes\). A third polyposis patient was identified harbouring a CNV loss located directly within the promoter 1B region of the APC tumour suppressor gene \((5:112,065,033-112,096,002, 31\ Kb; 91\%\) confidence and detected by 56 probes\) (Fig. 4). TaqMan CN assays confirmed the loss of this region in the affected patient and her two affected sons that were also recruited into the current study indicating this CN loss has been transmitted from one generation to the next. The loss of this region is likely to have contributed to disease development in all affected individuals.

### 3.5. Rare CNV events

The CNV dataset was also compared against the DGV. CNVs that were rare (not identified in the DGV and herein termed rare CNVs) corresponded to 31.29\% (87 of 278) of the total CNVs identified in both patients and controls. In the control cohort 28.85\% (30 of 104) of CNVs detected in 19 of the 40 controls (32.56\%) were classified as rare whereas 32.76\% (57 of 174) of CNVs detected in 23 of the 56 patients (41.07\%) were rare. No significant difference was detected in the number of rare CNVs between patients and controls \((p = 0.57)\). In total, 49 genes were associated with the 57 rare CNVs identified in the polyposis cohort representing genes most likely to be associated with disease (see Table 4). With the exception of ANKFN1, FAM184B, and HCN1 (CNV loss) and CCDC19 (CNV gain) which were not expressed in normal colon tissue and four other genes (SNORD12, SNORD12B, SNORD12C, C20orf199)
Table 3
The 10 genes associated with CNVs unique to polyposis patients (identified as FAP11-16). Note the disrupted gene (its symbol and description), if the gene is expressed in the colon (www.proteinatlas.org), the CN type observed in the current dataset and a general column outlining the predicted interpretation of the effect different types of CNVs have on disease development.

| Gene    | Description                                           | Expression in colon | CN type          | Region of gene disrupted                                                                 | Interpretation (predicted)                                                                 |
|---------|--------------------------------------------------------|---------------------|------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| EVI2B   | ectopic viral integration site 2B                     | medium              | Gains            | FAP11: whole gene                                                                      | Whole gene duplication: increased expression/amplification of gene function.               |
| EVI2A   | ectopic viral integration site 2A                     | medium              | Gains            | FAP11: whole gene                                                                      | Whole gene duplication: increased expression/amplification of gene function.               |
| MAP2    | small ArfGAP2                                          | medium              | Gains            | FAP12: part gene, exon and intron 1                                                     | Partial duplication or deletion involving introns and exons: disruption of gene function.  |
| BOD1L   | biorientation of chromosomes in cell division 1-1     | medium              | Gains            | FAP12: part gene, introns and exons                                                     | Partial duplication or deletion involving introns and exons: disruption of gene function. |
| NAMPT   | nicotinamide phosphoribosyltransferase                 | medium              | Gains            | FAP12: part gene, most of it from start of gene                                        | Partial duplication involving promoter: transcription of aberrant transcript leading to non-functional protein product/loss of gene function. |
| NFI1    | neurofibromin 1                                        | medium              | Gains            | FAP11: part gene, intronic and exon                                                    | Partial duplication involving exons: possible addition of duplicated exons into gene transcript creating a non-functional protein product/loss of gene function. |
| HSD11B1 | hydroxysteroid (11-beta) dehydrogenase 1              | low                 | Gains            | FAP12: part gene, upstream into exon 1                                                   | Partial duplication involving exons: possible addition of duplicated exons into gene transcript creating a non-functional protein product/loss of gene function. |
| GOS2    | GO/G1 switch 2                                         | medium              | Gains            | FAP12: part gene, upstream into exon 1                                                   | Partial duplication involving exons: possible addition of duplicated exons into gene transcript creating a non-functional protein product/loss of gene function. |
| DOCK4   | dedicator of cytokinesis 4                            | low                 | Both             | FAP11: part gene dup, intronic                                                         | Partial duplication or deletion involving introns: development of cryptic splice sites or the formation of pseudo exons leading to disruption in gene expression/loss of gene function. |
| A2BP1   | RNA binding protein, fox-1 homolog (C. elegans) 1     | low                 | Both             | FAP11: part gene dup, intronic                                                         | Partial duplication or deletion involving introns: development of cryptic splice sites or the formation of pseudo exons leading to disruption in gene expression/loss of gene function. |

where no information was available. 41 genes have been reported to be expressed in the colon and rectum (www.proteinatlas.org).

3.6. Pathway analysis and miR annotation of rare genes in polyposis patients

The 45 of the 49 rare genes were successfully mapped and investigated further using WebGestalt pathway analysis (Zhang et al., 2005) for enrichment among KEGG pathways, cytogenetic band regions and 3’UTR regions of genes (i.e. miR targets).

KEGG analysis revealed no significant pathways however, enrichment among cytogenetic bands identified 11 cytobands (20q13, 17q25, 6q14, 20q, 1q25, 6q, 2p13, 11q23, 1q32, 17q and 5q31; all with \( p < 0.0443 \); see Table 9 in Masson et al., submitted for publication) that were associated with 22 of the 49 rare genes (see Table 10 in Masson et al., submitted for publication). Enrichment analysis for the targets of miRs identified 26 significant regions (all with \( p < 0.0421 \)) within the 3’UTR of 19 of the 49 rare genes for which 42 miRs were suggested to target (see Tables 8 and 9 in Masson et al.))

TAM31 of the 42 miRs subsequently identified a total of 161 miR categories: 10 families, 13 clusters, 34 functional categories, 102 Human miR associated disease database (HMDD) and 2 tissue specificity categories. Specifically, miRs were significantly over-represented in the family category miR-15 (miR-15a, miR-195, miR-15b and miR-16; \( p = 0.002 \)) and the HMDD categories for glioblastoma (miR-15a, miR-195, miR-16, miR-181a-c, miR-18a and miR-32; \( p = 0.0205 \)), breast neoplasia (miR-15a, miR-520a, miR-320, miR-200a, miR-181b, miR-135b, miR-135b, miR-497, miR-133a, miR-27a, miR-302c, miR-18a, miR-195, miR-30a, miR-18b and miR-519c; \( p = 0.002 \)) and leukaemia (miR-15a, miR-181a, miR-181b and miR-16; \( p = 0.008 \)).

4. Discussion

CNVs have yet to be intensively investigated for their involvement in polyposis and consequent contribution to disease development. Here we have presented a comparison between 56 unrelated APC and MUTYH mutation negative patients all diagnosed with polyposis and 40 healthy controls. We have furthermore compared our results the COSMIC database and DGV and have assessed our data in terms of CNV abundance, size and distribution using a whole genome approach in search of genes and genomic regions that could be associated with polyposis.

An increased CNV burden has been suggested to be associated with an increased risk of disease development, while variation in CNV burden is associated with phenotypic variation (Girirajan and Eichler, 2010). We did not identify any significant differences in the number or size of CNVs between polyposis patients and controls. This finding suggests that the numerical burden of CNVs (>6.03 Kb) does not appear to contribute to an increased disease risk. However, since our analysis was limited to the detection of CNVs greater than 6.03 Kb we cannot rule out the involvement of smaller CNVs in the aetiology of this disease.

This study revealed several CNVs affecting recurrent loci that included genes known to be associated with CRC, in multiple patients: DOCK4 variants have been reported to give rise to various cancers including ovarian, prostate, glioma and CRC (Kuo et al., 2009); DOCK4 is also involved with the regulation of β-catenin in the WNT signalling pathway (Upadhayay et al., 2008), which has been directly implicated in FAP development; NAMPT, which is involved in the metabolism and proliferation of cells (Zhang et al., 2012), has been identified to be over-expressed in CRC (Hufston et al., 1999); NAMPT is also a target of mir-26b (a putative tumour suppressor-miR) which binds to the 3’ UTR of NAMPT (Zhang et al., 2013); while duplications in the NFI gene have also been observed.
in CRCs (Cacev et al., 2005) suggesting that CNVs associated with these genes contribute to disease.

Furthermore, two of the recurrent CNV deletions observed in the current study also fell into regions containing recurrent deletions peaks reported by the TCGA for colon adenocarcinoma tumour data (located 16p13.3 and 7q 31.3), one of which is reported to harbour the disease candidate gene \textit{A2BP1} (Cancer Genome Atlas, 2012). Several other CNV regions identified among patients in the present study were also recurrent in the TCGA dataset (located 11q22.3, 15q21.1, 1p33, 20p12.1, 5q22.2, 7q31.3 and 5p12) containing several candidate disease genes including \textit{APC}, \textit{B2M}, \textit{AGBL4}, \textit{MACROD2} and \textit{HCN1}. Overall the results from the current study are consistent with previous reports on CNV burden in CRC, however our data suggests several additional genomic regions may contribute to disease in these polyposis patients.

The distribution of CNVs on individual chromosomes was also compared between patients and controls, which failed to reveal any significant difference in the frequency of total CNVs between the two groups. The frequency of CNVs on each chromosome could not be shown to be significantly different, but a trend was observed indicating a greater number of CNVs on chromosome 18 compared to the controls. Among these CNVs was a gain in the \textit{DCC} gene (identified in one patient). \textit{DCC} is reported as a tumour suppressor and is frequently observed to be down-regulated in CRC (~70% of patients) which has been attributed to the loss of genomic material in the 18q21 region in which \textit{DCC} resides (Fearon et al., 1990; Thiagalingam et al., 1996). Here we report the possible loss of \textit{DCC} gene function as a result of an intronic CN gain. It has been revealed by others that some deep intronic variants have been shown to contribute to CRC via the formation of pseudoexons, the activation of cryptic splice sites and the expression of aberrant mRNA transcripts (Spier et al., 2012). Validation studies using TaqMan CN assays confirmed the CN gain in the affected patient, however further studies will be required to understand the role of \textit{DCC} in CRC.

Intriguingly CN losses rather than CN gains were shown to be statistically enriched on chromosome 18 in polyposis patients. We observed a region of CN loss at 18p11.32 that affects nearly 9% of the polyposis patients in our study. GWAS and meta-analysis studies have previously recognized 18p11.32 as susceptibility loci for bipolar disease, childhood acute lymphoblastic leukemia (ALL) and leisure time exercise behaviour (De Moor et al., 2009; Ferreira et al., 2008; Trevino et al., 2009). More recently, loss of heterozygosity (LOH) at 18p11.32 has been reported in CRC adenomas (but not normal mucosa) and is suggested to be involved in CRC tumour development (Costi et al., 2011); and a second study reporting genomic losses at 18p11.32 in CRCs are suggesting that this region is associated with adenoma-carcinoma progression (Shi et al., 2012). Of particular note was the occurrence of the recently reported lncRNA (TCONS_00026231) residing in this region of loss. LncRNAs (non-coding nucleotides, 200-100,000 bp in size) are proposed to be master regulators whose functions include post-transcriptional regulation of gene expression, regulation of epigenetic marks, gene activation in \textit{cis} and they have been shown to influence processes such as pluripotency (Loewer et al., 2010; Nagano et al., 2008; Orom et al., 2010). Validation studies using TaqMan CN assays confirmed the CN losses in all affected patients. The frequency of this variant in a series of polyposis patients

**Fig. 2.** CNV results for the duplication in the \textit{DCC} gene in an FAP patient (FAP6). (A) CNV profile from Cyto2.7M array data using ChAS noting the defined CN region (dark box above gene representing the CN deletion) in relation to the log ratio plot (relative fluorescence of each probe, dot, on the array showing a decrease in fluorescence indicating a loss in genomic material) and the CN state (0 = normal two copies present, +1 = one extra copy, +2 = two extra copies, -1 = one less copy and -2 = two less copies); (B) Validation using TaqMan CN assay showing results for assay Hs03995741_cn noting the normal two copies of this region identified in the control (CON1), confirmation of the aberrant three copy in the affected FAP patient and the error bars associated with the three technical repeats for each sample; and (C) Location of CN duplication with respect to the gene and the TaqMan CN assays used in validating the variants.
suggests that it may be associated with a predisposition of CRC in a proportion of APC/MUTYH mutation negative patients. Further studies are required to ascertain the precise involvement of this lncRNA in the genesis of CRC and more specifically whether it is involved in controlling WNT signalling and therefore adenomatous polyposis development.

Investigation of CNVs residing in or in the proximity of known cancer genes or pathways may expand our understanding of their contribution to disease risk in polyposis. Herein we interrogated the CNV data in search for variants associated with genes in the WNT signalling and MMR pathways focusing on APC and MUTYH(Pezzi et al., 2009; Molatore et al., 2010). CNVs arising in or in the proximity of any of these genes may contribute to disease directly or via more cryptic means. Two unrelated polyposis patients harboured CNVs near MLH1 and CTNNB1. Germline variants arising in MLH1 are typically associated with Lynch syndrome(Rustgi, 2007); whereas mutations associated with CTNNB1 occur in sporadic CRC and other malignancies(Hirata et al., 2012; Sygut et al., 2012); furthermore mutations in CTNNB1 are reported to be enriched in desmoid disease(Le Guellec et al., 2012), the second major cause of mortality in FAP. Interestingly the TCGA results on colon adenocarcinoma also reports CTNNB1 as one of the most significantly mutated genes in (5%) non-hypermutated colon tumours(Cancer Genome Atlas, 2012). The involvement of these two genes is concordant with both Lynch syndrome and FAP, respectively(Jasper et al., 2010).

We identified a genomic loss located directly within the promoter 1B region of APC. It has been estimated that up to 2% of the mutations identified in FAP cases are large deletions, including deletions that

---

**Fig. 3.** CNV results for 18p11.32 deletion in the FAP patients (FAP1, FAP2, FAP3, FAP4 and FAP5). (A) CNV profile from Cyto2.7M array data using ChAS noting the defined CN region (dark box above gene representing the CN deletion) in relation to the log ratio plot (relative fluorescence of each probe, dot, on the array showing a decrease in fluorescence indicating a loss in genomic material) and the CN state (0 = normal two copies present, +1 = one extra copy, +2 = two extra copies, -1 = one less copy and -2 = two less copies); (B) Validation using TaqMan CN assay showing results for assay Hs03990520_cn noting the normal two copies of this region identified in the control (CON2), confirmation of the aberrant one copy in all affected FAP patients and the error bars associated with the three technical repeats for each sample; and (C) Location of CN deletions with respect to each other and the TaqMan CN assays used in validating the variants.
extend from the promoter into the coding region (Gismondi et al., 1998). Of APC’s two promoter regions, promoter 1A and 1B, the latter of these is suggested to only play a minor role in APC gene regulation (Tsuchiya et al., 2000). The first report attempting to characterize promoter-specific deletions in FAP was described in 2008 (Charames et al., 2008), while (Rohlin et al., 2011) has recently reported the first evidence of promoter 1B involvement in FAP which was associated with a partial deletion of this region. Validation studies using TaqMan CN assays confirmed the CN loss in the affected patient. As the patient’s two affected sons were also verified to carry the same CN loss confirming that the variant was transmitted from one generation to the next, this CN is likely to be the cause of disease in all the affected family members. Our study further supports the role of APC promoter 1B inactivation in FAP development, which is reinforced by the finding that the CNV is transmitted across generations and is suggested to segregate with the expected phenotype. It should also be noted that deep intronic mutations (smaller than the level of detection) in the APC gene and low level somatic mosaicism are reported to account for a proportion of polyposis patients (Spier et al., 2012; Aretz et al., 2007) and may remain a possible unexplored cause of disease in a fraction of the other patients in this cohort.

In this study we also compared CNV data from the patient cohort to the DGV, a much larger control database than that available from the current study. A list of 49 rare genes was revealed that were likely to contribute to the identification of genes and genomic regions associated with polyposis development and/or progression. Microarray analysis has identified several previously reported CRC susceptibility genes affected by CNVs in several patients, including MLH1, CTNNB1 and APC. We have also identified chromosome 18 to be a region of interest since loss of 18p11.32 in multiple unrelated patients is associated with a lncRNA that may provide insight into their potential contribution to disease. Several cytogenetic bands that were enriched in the analysis have previously been associated with CRC (20q13, 20q, 10q25, 6q, 11q23, 1q32 and 5q31) (Houlston et al., 2010; Jia et al., 2013; Jiao et al., 2012; Peters et al., 2012, 2013; Tenesa et al., 2008; Cui et al., 2011). Of particular interest was the enrichment of 11q23 which has recently been reported to harbour risk variants for genetically unexplained colorectal adenomatous polyposis (Hes et al., 2014). The findings in the current study provide further support for the possible involvement of this region.

Annotation of the 42 miRs proposed to target the enriched 3’UTR miR target region of the 49 rare genes further identified the miR-15 family to be overrepresented which is particularly interesting given this family is has been reported to be associated with tumour suppression (Calin et al., 2002; Roccaro et al., 2009). In CRC more specifically, targeting the miRs miR-15 and miR-16 has been suggested as an effective mechanism to inhibit the growth of CRCs (Dai et al., 2012).

In conclusion, this study has revealed a number of CNVs which may contribute to the identification of genes and genomic regions associated with polyposis development and/or progression. In silico analysis was undertaken in search for biologically meaningful relationships among these 49 genes to provide insight into their potential contribution to disease.
be involved in disease development. Overall the results of this study provide further evidence for the involvement of CNVs in the aetiology of polyposis.

Author contributions

ALM conducted the experiments, performed data analysis/interpretation and wrote the first draft of the manuscript. BAT-P and T-JE provided expertise in data analysis and interpretation and wrote the final version of the manuscript prior to submission. PM provided statistical expertise. ADS enabled patient recruitment into this study. GNH provided critical review of the manuscript and helped design the experiments.

Table 4

| Gene      | Description                                      | Expression |
|-----------|--------------------------------------------------|------------|
| ADD3      | adducin 3 (gamma)                                | High       |
| AIM1      | absent in melanoma 1                             | Medium     |
| AMICA1    | adhesion molecule, interacts with CXADR antigen 1| Medium     |
| ANKIN1    | containing 1                                     | Not        |
| APC       | adenomatous polyposis coli                       | Low        |
| ARHGAP25  | Rho GTPase activating protein 25                 | Low        |
| ARHGAP26  | Rho GTPase activating protein 26                 | Medium     |
| ARHGDIIB  | Rho GDP dissociation inhibitor (GDI) beta        | High       |
| BC2AR     | BC2-related protein A1                           | Low        |
| BOD1L     | biorientation of chromosomes in cell division 1-1| Medium     |
| C17orf95  | methyltransferase like 23                       | Medium     |
| C20orf199 | ZNF1 antisense RNA 1                             | Unknown    |
| C5orf56   | chromosome 5 open reading frame 56               | Low        |
| CCD1C1    | coiled-coil domain containing 19                 | Medium     |
| CDH11     | cadherin 11, type 2, OB-cadherin (osteoblast)     | Medium     |
| CEACAM6   | molecule 6 (non-specific cross-reacting antigens)| High       |
| DDX10     | DEAD (Asp-Glu-Ala-Asp) box polypeptide 10        | Ets variant 6 |
| ET6V      | Ets related factor 6                            | Not        |
| FAM184B   | family with sequence similarity 184, member B    | Medium     |
| FKBPLA    | FK506 binding protein 1A, 12kd                  | High       |
| G0S2      | G0/G1switch 2                                   | Medium     |
| GALC      | galactosylceramidase                             | Medium     |
| GAST      | growth arrest-specific 7                        | Medium     |
| GPP65     | G protein-coupled receptor 65                    | Not        |
| HCN1      | hyperpolarization activated cyclic nucleotide-gated potassium channel 1 | Detected |
| HSD11B1   | hydroxysteroid (11-beta) dehydrogenase 1         | Medium     |
| JMD8      | jumonji domain containing 6                     | Medium     |
| LAMB3     | laminin, beta 3                                 | Medium     |
| LCAS      | Leber congenital amaurosis 5                     | Medium     |
| MFSD11    | major facilitator superfamily domain containing 11 | Medium     |
| MNP3L     | myelin protein zero-like 3                       | Medium     |
| MXRAT     | matrix-remodelling associated 7                  | Medium     |
| NAMP/T    | nicotinamide phosphoribosyltransferase           | Medium     |
| NUMA1     | nuclear mitotic apparatus protein 1              | Medium     |
| PLEK      | pleckstrin                                      | Medium     |
| QKI       | QKI, KH domain containing, RNA binding           | Medium     |
| RFT1      | RFT1 homolog (S. cerevisiae)                     | Medium     |
| SEL1      | selectin 1                                      | Low        |
| SFRS2     | arginine/serine rich splicing factor 2           | High       |
| SH3BGR2   | SH3 domain binding glutamic acid-rich protein 2  | Medium     |
| SMAP2     | small ArfGAP2                                   | Medium     |
| SMC3      | structural maintenance of chromosomes 3         | Medium     |
| SNORD12   | small nuclear RNA, C/D box 12                   | Unknown    |
| SNORD12B8 | small nuclear RNA, C/D box 12B                  | Unknown    |
| STX17B    | serine/threonine kinase 17                      | Medium     |
| STX8      | syntaxin 8                                      | High       |
| TAGLN2    | transgelin 2                                    | Medium     |
| ZNF51     | zinc finger, NFX1-type containing 1              | Medium     |

RJS conceived the study, designed the experimental approach and reviewed and approved the final version of the manuscript prior to submission.

Additional information

This work has been supported by the following funding bodies and Institutions: Australian Rotary Health/Rotary District 9650, the Commonwealth Scientific and Industrial Research Organization (CSIRO), the University of Newcastle and the Hunter Medical Research Institute.

Competing Financial Interests

The author(s) declare no competing financial interests.

References

Aretz, S., et al., 2007. Somatic APC mosaicism: a frequent cause of familial adenomatous polyposis (FAP). Hum. Mutat. 28, 985–992.

Cacev, T., Radosevic, S., Spaventi, R., Pavelic, K., Kapitanovic, S., 2005. NFI gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 54, 1129–1135.

Calin, G.A., et al., 2002. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 99, 15524–15529.

Cancer Genome Atlas, 2012. N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337.

Chan, T.L., et al., 2001. A novel germline 1.8-kb deletion of hMLH1 mimicking alternative splicing: a founder mutation in the Chinese population. Oncogene 20, 2976–2981.

Charames, G.S., et al., 2008. A large novel deletion in the APC promoter region causes gene silencing and leads to classical familial adenomatous polyposis in a Manitoba Mennonite kindred. Hum. Genet. 124, 535–541.

Clendinnen, M., et al., 2011. Mutation deep within an intron of MSH2 causes Lynch syndrome. Familiy Cancer 10, 297–301.

Cost, R., et al., 2011. Repeated atostomatic recurrence of colorectal tumors: genetic analyses of two cases. World J. Gastroenterol. 17, 3752–3758.

Cui, R., et al., 2011. Common variant in 6q25-6q71 is associated with distal colon cancer in an Asian population. Gut 60, 799–805.

Dai, L., et al., 2012. Vector-based miR-15a/16-1 plasmid inhibits colon cancer growth in vivo. Cell Biol. Int. 36, 755–770.

De Moor, M.H., et al., 2009. Genome-wide association study of exercise behavior in Dutch and American adults. Med. Sci. Sports Exerc. 41, 1887–1895.

Fearon, E.R., et al., 1990. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247, 49–56.

Ferreira, M.A., et al., 2008. Collaborative genome-wide association studies supports a role for ANK3 and CACNA1C in bipolar disorder. Nat. Genet. 40, 1056–1058.

Fokkema, I.F., et al., 2011. LOVD v2.0: the next generation in gene variant databases. Hum. Mutat. 32, 557–567.

Gallatatos, P., Foulkes, W.D., 2006. Familial adenomatous polyposis. Am. J. Gastroenterol. 101, 385–398.

Girirajan, S., Eichler, E.E., 2010. Phenotypic variability and genetic susceptibility to genomic disorders, Hum. Mol. Genet. 19, R176–R187.

Gismondi, V., et al., 1998. 310 basepair APC deletion with duplication of breakpoint (439ins15del310) in an Italian polyposis patient. Hum. Mutat. (Suppl. 1), S220–S222.

Hes, F.J., et al., 2014. Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. J. Med. Genet. 51, 55–60.

Hetzenecker, A.M., et al., 2012. Downregulation of the ubiquitin-proteasome system in normal colonic macrophages and reinduction in inflammatory bowel disease. Digestion 86, 34–47.

Hirata, H., et al., 2012. MicroRNA-1826 targets VEGFC, beta-catenin (CTNNB1) and MEK1 mimics. Mod. Pathol. 25, 1551–1558.
